Valiant Laboratories Ltd

Valiant Laboratories Ltd

₹ 105 0.86%
22 May - close price
About

Incorporated in 1980, Valiant Laboratories
Ltd manufactures and deals in Pharmaceuticals and speciality chemicals[1]

Key Points

Business Overview:[1][2]
VLL is in the active pharmaceutical ingredient manufacturing business. It manufactures finished dosage forms of paracetamol API viz. Tablets, Capsules, and Other medications. Paracetamol API is a key ingredient used to treat a variety of conditions including Headache, Arthritis, Muscle Aches, Toothache, Backache, Cold, and Fever

  • Market Cap 454 Cr.
  • Current Price 105
  • High / Low 158 / 75.2
  • Stock P/E
  • Book Value 53.9
  • Dividend Yield 0.00 %
  • ROCE -0.43 %
  • ROE -0.91 %
  • Face Value 10.0

Pros

Cons

  • Company has low interest coverage ratio.
  • Company has a low return on equity of 4.89% over last 3 years.
  • Company has high debtors of 197 days.
  • Working capital days have increased from 133 days to 195 days

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025
87.96 70.77 89.92 51.41 59.55 40.52 30.58 18.88 21.48 35.23 57.77
77.28 60.84 81.30 47.59 60.94 46.83 35.11 21.27 28.21 34.61 53.94
Operating Profit 10.68 9.93 8.62 3.82 -1.39 -6.31 -4.53 -2.39 -6.73 0.62 3.83
OPM % 12.14% 14.03% 9.59% 7.43% -2.33% -15.57% -14.81% -12.66% -31.33% 1.76% 6.63%
1.47 0.78 1.72 2.44 2.96 1.78 2.50 2.17 1.93 0.67 0.65
Interest 0.17 0.04 0.03 0.02 0.02 0.02 0.02 0.05 0.01 0.06 0.05
Depreciation 0.37 0.40 0.44 0.46 0.49 0.49 0.50 0.50 0.51 0.51 0.51
Profit before tax 11.61 10.27 9.87 5.78 1.06 -5.04 -2.55 -0.77 -5.32 0.72 3.92
Tax % 25.50% 25.51% 20.67% 26.12% 25.47% -30.75% -52.16% 31.17% 12.41% -122.22% 17.60%
8.66 7.65 7.83 4.27 0.79 -3.50 -1.22 -1.01 -5.98 1.60 3.24
EPS in Rs 5.32 4.70 2.40 1.31 0.24 -0.81 -0.28 -0.23 -1.38 0.37 0.75
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
182 292 334 182 133
132 249 299 190 138
Operating Profit 50 42 35 -8 -5
OPM % 27% 15% 11% -5% -4%
1 2 5 10 5
Interest 2 0 0 0 0
Depreciation 3 2 2 2 2
Profit before tax 47 42 38 -1 -1
Tax % 35% 34% 24% -145% 49%
31 28 29 0 -2
EPS in Rs 16.89 8.91 0.08 -0.49
Dividend Payout % 0% 0% 0% 0% 0%
Compounded Sales Growth
10 Years: %
5 Years: %
3 Years: -23%
TTM: -27%
Compounded Profit Growth
10 Years: %
5 Years: %
3 Years: %
TTM: 25%
Stock Price CAGR
10 Years: %
5 Years: %
3 Years: %
1 Year: -30%
Return on Equity
10 Years: %
5 Years: %
3 Years: 5%
Last Year: -1%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Equity Capital 10 16 33 43 43
Reserves 78 55 68 193 191
1 61 60 60 60
17 49 52 28 23
Total Liabilities 106 182 213 325 317
20 22 30 32 30
CWIP 0 1 0 0 0
Investments 0 0 34 119 165
87 158 149 174 122
Total Assets 106 182 213 325 317

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
9 2 23 49 -22
-17 -12 -21 -183 25
11 6 -2 136 -0
Net Cash Flow 4 -4 0 2 3

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Debtor Days 85 139 97 92 197
Inventory Days 18 25 17 22 12
Days Payable 37 72 62 54 61
Cash Conversion Cycle 66 91 52 60 149
Working Capital Days 103 111 106 98 195
ROCE % 38% 26% -2% -0%

Shareholding Pattern

Numbers in percentages

Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025
74.94% 74.94% 74.94% 74.94% 74.94% 74.94% 74.94%
8.64% 7.08% 3.48% 1.89% 0.00% 0.00% 0.64%
1.76% 0.43% 0.00% 0.00% 0.00% 0.00% 0.00%
14.66% 17.54% 21.58% 23.18% 25.06% 25.06% 24.42%
No. of Shareholders 37,43415,82114,91414,24915,18915,69215,036

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents